News: The European Medicines Agency (EMA)... has revealed it is reviewing rare blood clots suffered by recipients of the Johnson and Johnson vaccine in the United States.

Johnson and Johnson said it was aware of the review and was working with regulators to assess the issue, but insisted:

“No clear causal relationship has been established between these rare events and the Janssen COVID-19 vaccine”.

Why do they keep calling it "casual relationship"? Is that a nice way of saying 'side-effect'?

News:
Professor Mary-Louise McLaws, epidemiologist, University of New South Wales insisted the extremely rare complications in each of the vaccines far outweighed the threat of COVID-19 (sic - guessing they got that backwards):

"It's all about putting into proportion the risk of death to our elderly group who represent 100 per cent of all coronavirus deaths in Australia ... you want to protect them by vaccinating everybody, but particularly the young ones who have a greater risk of acquiring it and transmitting it.”

Johnson and Johnson has an efficacy rate of 66%, but that falls to "a 57% efficacy in their South Africa trial without accounting for those with the previous infection" - so probably less than 50%.